Next Article in Journal
De Novo Assembly and Discovery of Genes That Involved in Drought Tolerance in the Common Vetch
Next Article in Special Issue
Lipid–Protein Interactions in Niemann–Pick Type C Disease: Insights from Molecular Modeling
Previous Article in Journal
Osteochondral Tissue Regeneration Using a Tyramine-Modified Bilayered PLGA Scaffold Combined with Articular Chondrocytes in a Porcine Model
Previous Article in Special Issue
The Role of Dimethyl Sulfoxide (DMSO) in Gene Expression Modulation and Glycosaminoglycan Metabolism in Lysosomal Storage Disorders on an Example of Mucopolysaccharidosis
Open AccessReview

Molecular Pathways and Respiratory Involvement in Lysosomal Storage Diseases

1
Department of Medicine and Surgery, Università degli Studi di Milano Bicocca, Respiratory Unit, San Gerardo Hospital, ASST di Monza, 20900 Monza, Italy
2
Rare Metabolic Diseases Unit, Pediatric Department, Fondazione MBBM, Università degli Studi di Milano Bicocca, San Gerardo Hospital, ASST di Monza, 20900 Monza, Italy
3
Department of Neuroradiology, Università degli Studi di Milano Bicocca, San Gerardo Hospital, ASST di Monza, 20900 Monza, Italy
4
Department of Medicine and Surgery, Università degli Studi di Milano Bicocca, Nephrology Unit, San Gerardo Hospital, ASST di Monza, 20900 Monza, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(2), 327; https://doi.org/10.3390/ijms20020327
Received: 12 December 2018 / Revised: 10 January 2019 / Accepted: 11 January 2019 / Published: 15 January 2019
(This article belongs to the Special Issue Molecular Features of Lysosomal Storage Disorders)
Lysosomal storage diseases (LSD) include a wide range of different disorders with variable degrees of respiratory system involvement. The purpose of this narrative review is to treat the different types of respiratory manifestations in LSD, with particular attention being paid to the main molecular pathways known so far to be involved in the pathogenesis of the disease. A literature search was conducted using the Medline/PubMed and EMBASE databases to identify studies, from 1968 through to November 2018, that investigated the respiratory manifestations and molecular pathways affected in LSD. Pulmonary involvement includes interstitial lung disease in Gaucher’s disease and Niemann-Pick disease, obstructive airway disease in Fabry disease and ventilatory disorders with chronic respiratory failure in Pompe disease due to diaphragmatic and abdominal wall muscle weakness. In mucopolysaccharidosis and mucolipidoses, respiratory symptoms usually manifest early in life and are secondary to anatomical malformations, particularly of the trachea and chest wall, and to accumulation of glycosaminoglycans in the upper and lower airways, causing, for example, obstructive sleep apnea syndrome. Although the molecular pathways involved vary, ranging from lipid to glycogen and glycosaminoglycans accumulation, some clinical manifestations and therapeutic approaches are common among diseases, suggesting that lysosomal storage and subsequent cellular toxicity are the common endpoints. View Full-Text
Keywords: lysosomal storage diseases; lung involvement; mucopolysaccharidosis; mucolipidoses; Pompe disease; Niemann-Pick disease; Gaucher’s disease; Fabry disease lysosomal storage diseases; lung involvement; mucopolysaccharidosis; mucolipidoses; Pompe disease; Niemann-Pick disease; Gaucher’s disease; Fabry disease
Show Figures

Graphical abstract

MDPI and ACS Style

Faverio, P.; Stainer, A.; De Giacomi, F.; Gasperini, S.; Motta, S.; Canonico, F.; Pieruzzi, F.; Monzani, A.; Pesci, A.; Biondi, A. Molecular Pathways and Respiratory Involvement in Lysosomal Storage Diseases. Int. J. Mol. Sci. 2019, 20, 327.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop